Truist Cuts Insulet (PODD) PT but Maintains Buy as Top MedTech Pick for 2026

Group 1 - Insulet Corporation (NASDAQ:PODD) is recognized as one of the best growth stocks to buy in 2026, with a recent price target adjustment by Truist from $412 to $390 while maintaining a Buy rating [1] - Canaccord raised Insulet's price target to $450 from $432, reaffirming a bullish outlook on the MedTech sector for 2026, driven by consistent demand from an aging demographic and a robust M&A environment [2] - Evercore ISI initiated coverage of Insulet with an Outperform rating and a price target of $370, highlighting the company's unique tubeless design as a key factor in revolutionizing the insulin pump market [3] Group 2 - Truist expressed a more positive outlook on the healthcare sector for 2026, citing increasingly attractive relative valuations, but cautioned that the sector may serve as a source of funds rather than a primary destination for new capital [1] - Canaccord emphasized that Insulet is well-positioned for a multi-year cycle of outperformance due to recent label expansion and the rollout of Automated Insulin Delivery systems for Type 2 diabetes patients [2] - The overall sentiment in the MedTech sector is optimistic, with expectations of heightened focus on acute healthcare requirements and an increasing openness to new IPOs [2]